罗氏将完成15亿美元收购美国生物制药公司Poseida

智通财经

2025/01/08

智通财经APP获悉，罗氏(RHHBY.US)周三表示，计划完成对美国生物制药公司Poseida Therapeutics(PSTX.US)的收购。据了解，Poseida专注于开发多种类型癌症的复杂免疫细胞疗法。罗氏表示，已接受支付Poseida近6500万股股份，相当于该公司股票的66%，股东以每股9美元的价格出价，并额外支付每股高达4美元的或有付款。考虑到这一因素，该交易的价值将高达约15亿美元...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2501145617"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2501145617\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2501145617?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-01-08 15:52","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2501145617","market":"us","top_or_hot":-1,"title":"罗氏将完成15亿美元收购美国生物制药公司Poseida","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，罗氏(RHHBY.US)周三表示，计划完成对美国生物制药公司Poseida Therapeutics(PSTX.US)的收购。据了解，Poseida专注于开发多种类型癌症的复杂免疫细胞疗法。罗氏表示，已接受支付Poseida近6500万股股份，相当于该公司股票的66%，股东以每股9美元的价格出价，并额外支付每股高达4美元的或有付款。考虑到这一因素，该交易的价值将高达约15亿美元...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010815573195fc8d21&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>罗氏将完成15亿美元收购美国生物制药公司Poseida</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n罗氏将完成15亿美元收购美国生物制药公司Poseida\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-08 15:52 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010815573195fc8d21&s=b><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，罗氏(RHHBY.US)周三表示，计划完成对美国生物制药公司Poseida Therapeutics(PSTX.US)的收购。据了解，Poseida专注于开发多种类型癌症的复杂免疫细胞疗法。罗氏表示，已接受支付Poseida近6500万股股份，相当于该公司股票的66%，股东以每股9美元的价格出价，并额外支付每股高达4美元的或有付款。考虑到这一因素，该交易的价值将高达约15亿美元...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010815573195fc8d21&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PSTX","symbol_name":"Poseida Therapeutics, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010815573195fc8d21&s=b","article_id":"2501145617","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010815573195fc8d21&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2501145617","pubTimestamp":1736322752,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"据了解，Poseida专注于开发多种类型癌症的复杂免疫细胞疗法。罗氏表示，已接受支付Poseida近6500万股股份，相当于该公司股票的66%，股东以每股9美元的价格出价，并额外支付每股高达4美元的或有付款。罗氏称，在收购中，Poseida或罗氏不拥有的所有Poseida股份将转换为每股获得相同对价的权利。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"PSTX":"Poseida Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Roche to complete $1.5 billion acquisition of US biopharmaceutical company Poseida","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PSTX":0.9},"content_text":"智通财经APP获悉，罗氏(RHHBY.US)周三表示，计划完成对美国生物制药公司Poseida Therapeutics(PSTX.US)的收购。据了解，Poseida专注于开发多种类型癌症的复杂免疫细胞疗法。罗氏表示，已接受支付Poseida近6500万股股份，相当于该公司股票的66%，股东以每股9美元的价格出价，并额外支付每股高达4美元的或有付款。考虑到这一因素，该交易的价值将高达约15亿美元。该收购于去年11月宣布，是罗氏为弥补不断下降的肿瘤药物销售而扩大其研发管线的最新举措。罗氏周三表示：“今天晚些时候，罗氏打算完成对Poseida的收购……无需投票或召开Poseida股东大会。”罗氏称，在收购中，Poseida或罗氏不拥有的所有Poseida股份将转换为每股获得相同对价的权利。Poseida将成为罗氏的全资子公司，为后者增加所谓的同种异体CAR-T细胞疗法，该疗法使用转基因免疫细胞攻击癌症细胞或治疗自身免疫疾病。Poseida还致力于针对实体瘤和自身免疫性疾病的CAR-T项目。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}